ABSTRACT
indications for hospital admission [1] [2] [3] [4] . Hospitalizations for preterm labor (PTL) account for nearly 33% of all inpatient prenatal unit admissions; however, up to 85% of patients do not deliver within the next 7 days 5, 6 . This leads to unnecessary and potentially harmful treatments, including corticosteroids and tocolytics [7] [8] [9] . Approximately 65-75% of PTBs are spontaneous, while the remainder are iatrogenic 10 . Spontaneous PTB (sPTB) may be caused by several pathological processes 11, 12 ; thus, prediction of PTB has been a long-standing challenge, as clinical symptoms alone are not of adequate predictive accuracy 13, 14 . The most notable methods for the prediction of PTB are cervical-length (CL) measurement and biomarker tests based on fetal fibronectin (fFN), phosphorylated insulin-like growth factor-binding protein-1 (phIGFBP-1) or placental alpha microglobulin-1 (PAMG-1).
All three biomarkers have been evaluated in multiple clinical settings, and their performance shows considerable variation between studies, based on demographic and other factors underlying each cohort, such as the prevalence of sPTB within 7 days of testing, which ranges from 0.9% to 52% 15, 16 . Concomitantly, the predictive values associated with each biomarker also vary. Positive predictive values (PPV) for PAMG-1, fFN and phIGFBP-1 range from 23.1% to 100% 15, 17 , 4.3% to 92.3% 15, 18 and 2.2% to 81.3% 18, 19 , respectively, and negative predictive values (NPV) range from 93.0% to 100% 20, 21 , 73.2% to 100% 18, 22 and 61.8% to 98.4% 16, 19 , respectively. The range of predictive values presents a challenge to clinicians evaluating biomarker tests of their population, which may have a different pretest probability of sPTB ≤ 7 days from that reported by any one study. Although the impact of disease prevalence on the performance of a diagnostic test is well-established 23 , it has not yet been considered for sPTB.
This review has two objectives. First, to perform the most up-to-date systematic review and meta-analysis of the accuracy of PAMG-1, fFN and phIGFBP-1 for the prediction of sPTB ≤ 7 days after testing in symptomatic women using methods described in the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Second, to stratify the test performance of each biomarker according to the pretest probabilities of sPTB ≤ 7 days, associated with various CL measurement ranges, in women with symptoms of PTL and with clinically intact membranes and minimal (≤ 3 cm) cervical dilatation.
METHODS
This study followed a prospective review protocol and is reported in accordance with recommended methods for systematic reviews of diagnostic test accuracy using the PRISMA guidelines 24, 25 .
Literature review
We performed a literature search of studies reporting on the test performance of PAMG-1, fFN and phIGFBP-1 for the prediction of PTB within 7 days of testing in women with symptoms of PTL. Two reviewers searched independently the Cochrane, MEDLINE, PubMed and ResearchGate bibliographic databases, from inception to October 2017, using a combination of keywords including 'PartoSure', 'PAMG-1'; 'fetal fibronectin', 'ffn', 'fibronectin', 'Rapid fFN' or 'QuikChek'; 'ActimPartus' or 'phIGFBP-1'. Additional citations were identified through review of the proceedings and submitted abstracts of several international meetings and conferences focused on maternal-fetal medicine or PTB. All references in the retrieved articles were screened for further studies relevant to the objective of this review. Editorials and reviews, although themselves not included in the analysis, were also scanned for relevant studies.
Only prospective or cohort studies that met the following criteria were included in this analysis: (1) the clinical study objective was to determine the accuracy of specified biomarkers for the prediction of PTB; (2) the study reported or included sufficient information to calculate test performance metrics for the prediction of sPTB within 7 days of testing (i.e. the reference standard); (3) the study population had signs or symptoms suggestive of PTL, clinically intact membranes and minimal (≤ 3 cm) cervical dilatation; and (4) the study population included patients before 37 weeks' gestation. Studies were excluded if they had any of the following characteristics: (1) the clinical study objective was not to determine the accuracy of specified biomarkers for the prediction of PTB; (2) performance metrics for the prediction of PTB within 7 days of testing were not reported or could not be calculated through the information provided; (3) the test studied is not currently available commercially or was evaluated using a test procedure not recommended by the respective manufacturer; (4) the study was a reply or review article with no original data provided; or (5) the study duplicated performance metrics already reported by an earlier study. In case of uncertainty, the study authors were contacted to ensure that there was no overlap between study data.
Data extraction
Information was extracted independently for each primary study, using a purpose-designed data collection form to capture the study characteristics (i.e. authors, setting, year of publication, year and method of recruitment, prospective or retrospective data collection, percentage of women recruited included in the analysis), patient population characteristics (i.e. sample size, incidence of birth within 7 days and demographic information), inclusion and exclusion criteria (i.e. gestational age at sampling, singleton or multiple gestation, cervical dilatation, status of fetal membranes, presence of vaginal bleeding, intercourse in the previous 24 h, frequency of contractions, CL), PTB endpoint used for test performance calculations, and numbers of true-positive, false-positive, true-negative and false-negative test results for the prediction of sPTB within 7 days of testing. Studies with insufficient information were excluded from the meta-analysis.
Assessment of risk of bias
The quality of the included studies was assessed using a modified version of the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool 26 . All the included studies were judged as having 'low risk', 'high risk' or 'unclear risk' of bias and were evaluated and interpreted in consideration of the following characteristics: (1) patient selection (studies recruiting patients consecutively or randomly were considered to have low risk of bias, whereas those that used convenience sampling, arbitrary recruitment or non-consecutive recruitment were considered to have a high risk of bias); (2) reference standard (studies that had at least one of their endpoints defined as sPTB within 7 days of testing were considered to have a low risk of bias, whereas those that included endpoints defined simply as PTB, or iatrogenic or medically indicated PTB within 7 days of testing, were considered to have a high risk of bias); (3) blinding (studies stating clearly that clinicians managing patient care did not have knowledge of biomarker test results were considered to have a low risk of bias, whereas studies in which the managing clinicians had knowledge of biomarker test results were considered to have a high risk of bias); and (4) inclusion of patients in the analysis (studies including ≥ 85% of recruited patients into the calculations of test performance were considered to have a low risk of bias, whereas those that included < 85% of recruited patients into the calculations were considered to have a high risk of bias).
A summary score to estimate the overall quality of each study was not calculated, as interpretation of such summary scores may be potentially misleading 27 .
Data synthesis
When possible, data from individual studies were synthesized for singleton gestations. All included studies were stratified according to the pretest probability of sPTB ≤ 7 days of testing, into three predefined clinically relevant groups of low, intermediate or high risk. The probability of sPTB ≤ 7 days in patients with a CL measurement between 15 mm and 30 mm was used as reference for the intermediate-risk group. The three largest studies to date incorporating the use of a biomarker test along with CL measurements were selected as reference [28] [29] [30] . sPTB ≤ 7 days in this group of patients with CL between 15 mm and 30 mm was 7.5-10.7% (95% CI, 4.58-16.25%). The low-risk group was classified by rates of sPTB ≤ 7 days below the lower bound of the 95% CI (i.e. with pretest probability of sPTB ≤ 7 days < 4.58%) 28 . The intermediate-risk group was classified by rates of sPTB ≤ 7 days within the 95% CI (i.e. pretest probability of sPTB ≤ 7 days between 4.58% and 16.25%) [28] [29] [30] and the high-risk group by rates of sPTB ≤ 7 days above the upper bound of the 95% CI (i.e. pretest probability of sPTB ≤ 7 days > 16.25%) 30 .
Statistical analysis
Data extracted from each study were arranged in 2 × 2 contingency tables. Pooled estimates were obtained for each risk-classification group using a bivariate linear mixed model for the logit of sensitivity and specificity, with each diagnostic test as a covariate, as described in the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy 31 . As evaluation of the performance of the three diagnostic tests was a central aim of this meta-analysis, analysis was also performed using the bivariate linear mixed-effects model with the type of test as a covariate to assess differences in test accuracy measures 31 . Pooled estimates are reported from this same model for formal statistical comparison. The bivariate mixed model accounted for differences in study sample size as well as within-and between-study variability, while also accounting for correlation between sensitivity and specificity. Models were fit in SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) using PROC NLMIXED as described in the METADAS SAS macro [32] [33] [34] [35] [36] [37] . Model convergence could not be attained in the low-risk and intermediate-risk groups; therefore, the model was simplified to include random study effect only, without random effects, for sensitivity and specificity by study, thereby removing estimate of correlation between sensitivity and specificity from the model. Sensitivity and specificity with 95% CIs were calculated as estimated from the bivariate models with the differences between diagnostics tests evaluated on the logit scale. Likelihood ratios with 95% CIs were estimated thereafter from the pooled sensitivities and specificities of each biomarker test, with differences evaluated on the log scale. Similarly, the NPVs and PPVs for each risk-classification group were calculated using the pooled estimates of sensitivity and specificity. Standard errors and CIs were estimated based on the delta method with normal approximation. Global tests based on F-statistics were performed to assess the difference in outcomes among the three biomarker tests by each risk-classification group. Pairwise comparisons were evaluated from the model using t-statistic, and all the P-values were two-sided. All presented P-values are nominal with no adjustment for the test multiplicity, and statistical significance was set at P < 0.05.
Summary receiver-operating characteristics (ROC) curves were estimated according to the method of Rutter and Gatsonis 38 , as described also by Arends et al. 39 . The areas under the ROC curves (AUCs) were computed using the R package meta4diag (The R Foundation, Vienna, Austria), assuming the summary ROC curve being that of Rutter and Gatsonis 38 .
RESULTS

Study selection
Identification and selection of studies are summarized in Figure 1 . The database search identified 2339 citations, of which 2020 studies were excluded based on irrelevant
Excluded based on titles and duplicates (n = 2020)
Full-text articles reviewed (n = 319)
Excluded based on full article review (n = 254): Clinical study objective was not to determine accuracy of specified biomarker for prediction of PTB (n = 100) Performance metrics for prediction of PTB within 7 days of testing either were not reported or could not be calculated from information given (n = 84) No original data given (n = 38) Duplicate results (n = 25) Other (n = 7)
Relevant studies identified through search (n = 2339) Figure 1 Flowchart showing inclusion in systematic review of studies reporting on predictive accuracy of placental alpha microglobulin-1 (PAMG-1), fetal fibronectin (fFN) and phosphorylated insulin-like growth factor-binding protein-1 (phIGFBP-1) for the prediction of spontaneous preterm birth (PTB) within 7 days of testing in women with symptoms of preterm labor. Eleven studies included performance metrics for more than one biomarker.
titles and duplicates. The full-text articles of the remaining citations were reviewed, and a further 254 studies were excluded because either their clinical study objective was not to determine the accuracy of specified biomarkers for the prediction of PTB (n = 100), performance metrics for the prediction of PTB were not reported or could not be calculated from the data provided (n = 84), they did not include original data (n = 38), they reported duplicate results (n = 25) or for other reasons (n = 7). Characteristics of the 65 studies that were eventually included in the systematic review are summarized in Table S1 .
Study characteristics and risk of bias
Quality assessment of the included studies is summarized in Figure 2 . Seven (11%) studies fulfilled all four of the quality criteria, 23 (36%) fulfilled three quality criteria and the remaining 35 (54%) studies fulfilled two or fewer quality criteria, suggesting potential methodological flaws.
Overall, 14 studies (n = 2278 women) 15, 17, 20, 21, 30, [40] [41] [42] [43] [44] [45] [46] [47] [48] reporting on PAMG-1, 40 (n = 7431 women) 
Prediction of sPTB within 7 days of testing
Figures 3-5 show the sensitivity and specificity of the three biomarker tests for predicting PTB within 7 days of testing in symptomatic women, in each study. Three studies (n = 1074 women) 15, 40, 43 reporting on PAMG-1, eight studies (n = 2667 women) 15, 22, 40, 49, [52] [53] [54] [55] reporting on fFN and two studies (n = 559 women) 19 ,54 on phIGFBP-1 met the criteria to be included in the low-risk group. Nine studies (n = 929 women) 17, 21, 30, 41, [44] [45] [46] [47] [48] reporting on PAMG-1, 25 studies (n = 3714 women) 20 Fatkullin (2016) 45 Hadzi-Lega (2017) 48 Heverhagen (2015) 17 Konoplyannikov (2016) 47 Lotfi (2015) 44 Lou (2016) 46 Melchor (2018) 40 Nikolova (2015) 42 Nikolova (2017) 30 Ravi (2017) 43 Van Holsbeke (2016) 41 Wing (2017) Table 1 shows pooled summary sensitivity and specificity results for each biomarker test, overall and according to risk group, from the bivariate mixed model, with each diagnostic test as a covariate. PPV, NPV, positive (LR+) and negative likelihood ratios (LR-) were estimated using the bivariate mixed model from the sensitivities and specificities. PAMG-1 had a statistically superior PPV (P < 0.05) across all three risk-classification groups, demonstrating a 2-6-fold higher PPV than those of fFN and phIGFBP-1 (Table 1) . Pairwise comparisons of the NPV between tests did not show a statistically significant difference.
As the clinical usefulness of a diagnostic test may be largely determined by the accuracy with which it identifies its target disorder, this accuracy is best determined by 49 Benattar (1997) 62 Bruijn (2016) 28 Çekmez (2017) 20 Cheung (2013) 77 Closset (2001) 68 Desjardins (2008) 53 Diaz (2009) 75 Eroglu (2007) 73 Foxman (2004) 56 Gao (2014) 22 Giles (2000) 71 Gomez (2005) 74 Groom (2006) 59 Henrich (2010) 60 Iams (1995) 14 LaShay (2000) 55 Liong (2015) 66 Lopez (2000) 70 Lowe (2004) 63 Luzzi (2003) 58 MacDonald (2007) 50 Magro-Malosso (2017) 78 Malak (1996) 65 McKenna (1999) 72 Melchor (2018) 40 Nikolova (2015) 42 Peaceman (1997) 52 Riboni (2011) 54 Sakai (2003) 51 Senden (1996) 76 Skoll (2006) 69 Sümer (2010) 64 Swamy (2005) 57 Tekesin (2005) 61 Tripathi (2016) 18 Tsoi (2006) 67 van Baaren (2014) 29 Van Holsbeke (2016) 41 Wing (2017) assessing the likelihood ratios. LR+ above 10 and LRbelow 0.1 are considered to provide strong predictive evidence in most circumstances. Moderate prediction can be achieved with LR+ and LR-values of 5-10 and 0.1-0.2, respectively, whereas values below 5 and greater than 0.2, respectively, give only a minimal predictive accuracy 93 . LR+ showed a similar trend to the predictive values, with PAMG-1 having a statistically superior LR+ (P < 0.05) across all risk-classification groups, as compared with those of fFN and phIGFBP-1.
The PAMG-1 test was the only biomarker to have a LR+ above 10 in all three risk-classification groups, indicating strong predictive accuracy. On the other hand, comparison of LR-did not show any statistically significant difference between the different markers.
Furthermore, comparison of the AUCs of the three tests ( Figure 6 ) indicated that PAMG-1 had the highest predictive accuracy for sPTB within 7 days of testing, with phIGFBP-1 showing the lowest predictive accuracy. The AUCs for PAMG-1, fFN and phIGFBP-1 were 0.961, 0.874 and 0.801, respectively. When the bivariate model was fitted to each test separately for all available studies, the estimates of pooled sensitivity for PAMG-1, fFN and phIGFBP-1 for sPTB ≤ 7 days was 73.5% (95% CI, 63-82%), 75.3% (95% CI, 69-81%) and 71.0% (95% CI, 61-80%), respectively; pooled specificity was 96.6% (95% CI, 95-98%), 83% (95% CI, 80-86%), and 80.2% (95% CI, 76-84%), respectively; pooled LR+ was 21. Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Study Abo Ek-Ezz (2014) 92 Altinkaya (2009) 83 Azlin (2010) 82 Brik (2010) 81 Bruijn (2016) 28 Cooper (2012) 19 Danti (2011) 79 Eroglu (2007) 73 Fuchs (2017) 80 Hadzi-Lega (2017) 48 Kwek (2004) 89 Lembet (2002) 91 Nikolova (2017) 30 Park (2003) 87 Riboni (2011) 54 Sanchez Martinez (2006) 85 Singh (2013) 16 Sunagawa (2008) 88 Tanir (2009) 86 Ting (2007) 84 Tripathi (2016) 18 Winograd (2003) 
DISCUSSION
The findings of our systematic review suggest that PAMG-1 has a strong predictive accuracy for sPTB within 7 days of testing in women with signs and symptoms of PTL. The reported PPV for PAMG-1 was significantly higher than those of phIGFBP-1 and fFN biomarker tests, which have been used to rule out PTL because of their high NPVs. The positivity rate of each biomarker remained relatively consistent throughout the studies (7.9%, 23.0% and 29.7% for PAMG-1, fFN and phIGFBP-1, respectively). Given the potential of a positive biomarker test to influence the decision to admit and/or treat the patient, a test with a lower positivity rate and higher PPV may reduce the rate of unnecessary hospitalizations and in-utero transfers to tertiary-care centers and allow for more judicious use of therapeutic interventions such as antenatal corticosteroids and tocolytic agents.
The strength of this review stems from its rigorous methodology, which included stringent study selection criteria, recent literature searches and a highly specific focus area. Additionally, a modified version of the QUADAS-2 quality assessment tool was used to determine study quality, and contemporary statistical methods were used to obtain summary measures of the predictive accuracies.
Our study has some important limitations. First, it may be underpowered, as we were not able to attain convergence in the low-risk and intermediate-risk groups. Therefore, the model had to be simplified to include random study effects only, without random effects for sensitivity and specificity by study. Additionally, the three risk groups showed variation in sensitivity and specificity. These metrics should not be dependent on the prevalence of the disease, as compared to predictive values. This heterogeneity could be due to within-study error and/or other population characteristics. The reason for variation across populations should be further investigated. Second, the three biomarkers were not studied in the same number of subjects. Furthermore, only 45% of studies were considered to have a low risk of bias. Studies that did not specify the definition of PTB as spontaneous were ranked as having higher risk of bias as they may have included medically indicated deliveries. This effect is expected to be minimal, given that few studies fell into this group, and more than two-thirds of PTBs are spontaneous. Given the complexity and heterogeneity of available studies, the performance endpoints were limited to sPTB ≤ 7 days of testing, as not all studies included information for other endpoints, such as sPTB within 48 h or 14 days of testing.
Alternative analysis methods may produce different pooled estimates from those found in the present study. A simple pooled estimate may be obtained directly by summing numerators and denominators from the raw data across studies, but has severe limitations as it assumes lack of heterogeneity across the studies. Thus, random-effects models are required to describe variability in test accuracy across studies, which in addition assumes independence of sensitivity and specificity. The bivariate mixed-effects model of Reitsma et al. 36 is a widely accepted method for meta-analysis of diagnostic tests, as it overcomes the limitations of simple pooling by jointly modeling sensitivity and specificity. Apart from accounting for between-study variability due to both random error and inherent differences between the studies owing to different design, population or study procedures, the bivariate mixed-effects model method also allows for inclusion of covariates [33] [34] [35] [36] [37] . Lastly, our review did not assess the impact of test performance on patient management and resource economics. This is an area for future research. Additionally, the heterogeneity of each test's performance using individual-patient data and meta-regression techniques looking at covariates such as gestational age, contraction frequency and CL at presentation should also be examined in future studies.
To the best of our knowledge, this is the first systematic review to compare the performance of the PAMG-1, fFN and phIGFBP-1 biomarkers for the prediction of sPTB across different risk-classification groups. Although Boots et al. 94 discussed the effect of disease prevalence on test results, only the performance for a single pretest probability (20%) was reported. As the pretest probability of sPTB ≤ 7 days varied significantly between the publications (0.9% 15 to 52% 16 ), the predictive values for one population with a certain pretest probability may not apply to another. The pretest probabilities for sPTB ≤ 7 days can vary among populations owing to country-or center-specific algorithms for PTL diagnosis that call for the use of a biomarker test only with an equivocal diagnosis, such as CL between 15 and 30 mm 95 or those who present with any symptom of PTL and minimal cervical dilatation 15 . While our conclusions on the performance of fFN and phIGFBP-1 are consistent with those of previous systematic reviews 96, 97 , our work includes several studies published since these reviews were carried out. Furthermore, our study reaffirms the effect of prevalence (or pretest probability) on the performance of biomarker tests for the prediction of sPTB ≤ 7 days of testing.
Based on the probability of sPTB ≤ 7 days of testing in patients with CL between 15 mm and 30 mm reported in major publications [28] [29] [30] , the following clinical inferences may be drawn from our data: first, for regions or centers that do not routinely assess CL by transvaginal ultrasound (e.g. the US, UK), biomarker test performance for the prediction of sPTB ≤ 7 days would be commensurate with the performance reported for the low-risk group (PPV 34.4%, 9.1%, 6.1%, and NPV 98.9%, 99.0%, 98.5% for PAMG-1, fFN and phIGFBP-1, respectively); second, for regions or centers using biomarker tests only in patients with a CL between 15 and 30 mm (e.g. Europe), biomarker test performance for the prediction of sPTB ≤ 7 days would be commensurate with the performance reported for the intermediate-risk group (PPV 69.4%, 28.8%, 25.4%, and NPV 97.6%, 97.2%, 96.1% for PAMG-1, fFN and phIGFBP-1, respectively); third, for regions or centers that use biomarker tests only in patients with a CL of <15 mm, biomarker test performance for the prediction of sPTB ≤ 7 days would be commensurate with the performance reported for the high-risk group (PPV 82.9%, 50.3%, 53.7%, and NPV 92.4%, 77.6%, 96.3% for PAMG-1, fFN and phIGFBP-1, respectively).
In conclusion, even though all three biomarker tests had similar NPV and LR-, the PAMG-1 test had the highest PPV and LR+ across all risk stratification groups (P < 0.05). As such, our review supports the conclusions of the European Association of Perinatal Medicine guidelines, that the PAMG-1 test is the most accurate one to be used in women with a CL between 15 and 30 mm 95 .
